Should You Retain Labcorp Stock in Your Portfolio Right Now?

Zacks01-03

Labcorp Holdings Inc. LH, or Labcorp, is targeting high-growth areas as part of its expansion. By partnering with health systems and regional local laboratories, the company is leveraging science and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500821116?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-03 19:52","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2500821116","market":"us","top_or_hot":-1,"title":"Should You Retain Labcorp Stock in Your Portfolio Right Now?","media":"Zacks","content":"<div>\n<p>Labcorp Holdings Inc. LH, or Labcorp, is targeting high-growth areas as part of its expansion. By partnering with health systems and regional local laboratories, the company is leveraging science and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/retain-labcorp-stock-portfolio-now-115200267.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Retain Labcorp Stock in Your Portfolio Right Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Retain Labcorp Stock in Your Portfolio Right Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-03 19:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/retain-labcorp-stock-portfolio-now-115200267.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Labcorp Holdings Inc. LH, or Labcorp, is targeting high-growth areas as part of its expansion. By partnering with health systems and regional local laboratories, the company is leveraging science and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/retain-labcorp-stock-portfolio-now-115200267.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/retain-labcorp-stock-portfolio-now-115200267.html","article_id":"2500821116","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500821116","pubTimestamp":1735905120,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Labcorp Holdings Inc. LH, or Labcorp, is targeting high-growth areas as part of its expansion. By partnering with health systems and regional local laboratories, the company is leveraging science and innovation to lead in important therapeutic areas. Moreover, the LaunchPad initiative is contributing to strong margin performance. Yet, the adverse macroeconomic impacts and currency fluctuations may dent its growth.In the past year, this Zacks Rank #3  stock has risen 1.3% compared with the 1.2% growth of the industryand a 26.7% increase of the S&P 500 composite.The renowned healthcare diagnostics company has a market capitalization of $19.18 billion. In the trailing four quarters, the company delivered an average earnings surprise of 2.87%.Find the latest EPS estimates and surprises on ZacksEarnings Calendar.In addition, Labcorp acquired select assets from Invitae, reflecting its focus on specialty medicine and oncology. In July, the company expanded its collaboration with Ultima Genomi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","BK4007":"制药","BK4196":"保健护理服务","VCYT":"Veracyte Inc","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","BK4588":"碎股","BK4550":"红杉资本持仓","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","BK4198":"医疗保健用品","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","HAE":"美国血液技术","PAHC":"Phibro Animal Health Corporation","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LH":"徕博科","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4585":"ETF&股票定投概念"},"translate_title":"您现在应该在投资组合中保留Labcorp股票吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":1,"VCYT":1,"PAHC":1,"HAE":0.9},"content_text":"Labcorp Holdings Inc. LH, or Labcorp, is targeting high-growth areas as part of its expansion. By partnering with health systems and regional local laboratories, the company is leveraging science and innovation to lead in important therapeutic areas. Moreover, the LaunchPad initiative is contributing to strong margin performance. Yet, the adverse macroeconomic impacts and currency fluctuations may dent its growth.\nIn the past year, this Zacks Rank #3 (Hold) stock has risen 1.3% compared with the 1.2% growth of the industry and a 26.7% increase of the S&P 500 composite.\nThe renowned healthcare diagnostics company has a market capitalization of $19.18 billion. In the trailing four quarters, the company delivered an average earnings surprise of 2.87%.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nLet’s delve deeper.\nFactors at Play for Labcorp\nTargeted Development in High-Growth Area:  Labcorp is focusing more on key growth areas such as oncology, women’s health, autoimmune disease and neurology.The company has consistently reinforced its position as a preferred partner for health systems and regional local laboratories by harnessing science and innovation to expand its leadership in important therapeutic areas and by utilizing data and technology to bring important services and capabilities to its customers.\nIn August 2024, the company received the FDA’s de novo marketing authorization for the PGDx elio plasma focus Dx liquid biopsy test, which enables the laboratory to perform genomic profiling when tissue is limited or unavailable. The new Global Trial Connect suite of central laboratory solutions has received favorable responses from customers. Additionally, Labcorp’s Precision Oncology portfolio was expanded with newer strategic service offerings such as Labcorp Tissue Complete and OmniSeq INSIGHT circulating tumor DNA. Furthermore, the company is enhancing its consumer-initiated testing platform Labcorp on-demand with several tests, including syphilis and Luteinizing Hormone tests, and standard drugs.\nImage Source: Zacks Investment Research\nStrategic Acquisitions and Partnerships to Drive Growth: Labcorp’s latest agreement with Ballad Health involves acquiring certain of its outreach services to provide broader access to comprehensive testing and laboratory services, particularly in underserved rural areas. Labcorp also announced a collaboration with Florida-based Naples Comprehensive Healthcare and an agreement to acquire select assets of Lab Works, an independent clinical laboratory located in Alabama. In September, it closed the acquisition of select assets of BioReference Health's diagnostics business.\nIn addition, Labcorp acquired select assets from Invitae, reflecting its focus on specialty medicine and oncology. In July, the company expanded its collaboration with Ultima Genomics to utilize the company’s sequencing solution and technology. The companies will explore new whole genome sequencing clinical applications, including MRD in patients with early-stage solid tumor cancers.\nLaunchPad Initiative Right on Track: Labcorp implemented the LaunchPad initiative to improve business processes and achieve $350 million in savings by 2024.The company is on track to deliver $100 million to $125 million of savings this year through this initiative, consistent with its long-term target through 2024-2026.Labcorp has continued to focus on expanding its margins through the LaunchPad initiative. The benefits will be driven by rationalizing the location of facilities and talent, leveraging technological advancements and structural enhancements, integrating acquisitions and re-engineering the company’s systems and processes.\nFactors Weighing on LH\nMacroeconomic Risks: Labcorp relies on demand for diagnostic testing and drug development services from patients, physicians, hospitals and others. Macroeconomic volatilities including, inflation and potential recessions, may reduce demand and impact customer payments, affecting profitability. Additionally, geopolitical tensions in Ukraine and the Middle East could lower testing volumes, disrupt supply chain and raise costs.\nExposed to Currency Headwind: Labcorp's huge exposure in international markets makes it vulnerable to currency fluctuations. With the recent upward trend observed in the value of the U.S. dollar, further acceleration expected by analysts in this value will cause the company’s revenues to face a tough situation overseas. \nLH Stock Estimate Trend\nIn the past 30 days, the Zacks Consensus Estimate for Labcorp’s 2024 has remained constant at $14.52.\nThe Zacks Consensus Estimate for 2024 revenues is pegged at $12.99 billion, suggesting a 0.7% improvement from the 2023 comparable figure.\nTop MedTech Stocks\nSome better-ranked stocks in the broader medical space are Veracyte VCYT, Haemonetics HAE and Phibro Animal Health PAHC.\nVeracyte has an estimated 2024 earnings growth rate of 37.2% compared with the industry’s 15.3%. Veracyte’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 520.6%. Its shares have risen 44.5% compared to the industry’s 3.6% growth in the past year.\nVCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nHaemonetics, carrying a Zacks Rank #2 at present, has an estimated fiscal 2025 earnings growth rate of 15.9% compared with the industry’s 12.3%. Shares of the company have lost 8.3% against the industry’s 9.7% growth. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 2.82%.\nPhibro Animal Health, carrying a Zacks Rank #2 at present, has estimated earnings growth rate of 35.3% for fiscal 2025 compared with the industry’s 11.1%. Shares of the company have risen 77.6% compared with the industry’s 9.8% growth over the past year. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 25.47%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nLabcorp (LH) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nPhibro Animal Health Corporation (PAHC) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500821116"}